MTIM
AZN icon

Marathon Trading Investment Management’s AstraZeneca AZN Stock Holding History

Marathon Trading Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-61,300
Closed -$4.31M – 473
2014
Q4 		$4.31M Hold
61,300
– – 0.06% 167
2014
Q3 		$4.39M Buy
61,300
+50,000
+442% +$3.66M 0.12% 84
2014
Q2 		$839K Buy
+11,300
New +$817K 0.03% 169

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 28.54% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Marathon Trading Investment Management's AZN Position: Q3 2014 in Review

Marathon Trading Investment Management sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 13,087 shares — an estimated $958K sold.

Marathon Trading Investment Management first reported a position in AZN in Q2 2014 and held it in 1 quarter. The position peaked at $972K in Q2 2014. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

  • Marathon Trading Investment Management reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
  • Marathon Trading Investment Management sold 13,087 AstraZeneca shares in Q3 2014, an estimated $958K.
  • Marathon Trading Investment Management first reported a position in AstraZeneca in Q2 2014 and held it in 1 quarter.
  • Marathon Trading Investment Management's AstraZeneca position peaked at $972K in Q2 2014.
  • 402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Marathon Trading Investment Management's 13F filing for Q3 2014, filed 17 Feb 2015.